Literature DB >> 11098879

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

C J McDougle1, L E Kresch, D J Posey.   

Abstract

Repetitive thoughts and behavior are considered integral and core components of autistic disorder. Results from recent studies suggest that the types of repetitive thoughts and behavior of adults with autism and those with obsessive-compulsive disorder (OCD) may be different. Serotonin reuptake inhibitors (SRIs), the primary drug treatment for patients with OCD, may reduce the repetitive phenomena of some autistic patients. Two controlled studies of the nonselective SRI clomipramine have shown the drug to be more efficacious than the relatively selective norepinephrine reuptake inhibitor desipramine and placebo in children with autism. One controlled study of the selective SRI fluvoxamine found it to be significantly better than placebo for reducing repetitive phenomena and aggression in adults with autistic disorder. Additional research is needed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11098879     DOI: 10.1023/a:1005551523657

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN: 0162-3257


  44 in total

1.  Fluoxetine in autism with depression.

Authors:  M Ghaziuddin; L Tsai; N Ghaziuddin
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1991-05       Impact factor: 8.829

2.  Fluoxetine in autism.

Authors:  R D Todd
Journal:  Am J Psychiatry       Date:  1991-08       Impact factor: 18.112

3.  Maintenance of sameness in children with Kanner's syndrome.

Authors:  M Prior; M B Macmillan
Journal:  J Autism Child Schizophr       Date:  1973 Apr-Jun

4.  Failure in treating obsessive-compulsives.

Authors:  E B Foa
Journal:  Behav Res Ther       Date:  1979

Review 5.  Do autistic children have obsessions and compulsions?

Authors:  S Baron-Cohen
Journal:  Br J Clin Psychol       Date:  1989-09

6.  Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.

Authors:  C J McDougle; E S Brodkin; S T Naylor; D C Carlson; D J Cohen; L H Price
Journal:  J Clin Psychopharmacol       Date:  1998-02       Impact factor: 3.153

7.  Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report.

Authors:  C J McDougle; L H Price; W K Goodman
Journal:  J Autism Dev Disord       Date:  1990-12

8.  Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation.

Authors:  E S Brodkin; C J McDougle; S T Naylor; D J Cohen; L H Price
Journal:  J Child Adolesc Psychopharmacol       Date:  1997       Impact factor: 2.576

9.  Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.

Authors:  S H Fatemi; G M Realmuto; L Khan; P Thuras
Journal:  J Autism Dev Disord       Date:  1998-08

10.  Clomipramine ameliorates adventitious movements and compulsions in prepubertal boys with autistic disorder and severe mental retardation.

Authors:  J R Brasic; J Y Barnett; D Kaplan; B B Sheitman; P Aisemberg; R T Lafargue; S Kowalik; A Clark; M O Tsaltas; J G Young
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

View more
  22 in total

1.  Pharmacologic treatment of repetitive behaviors in autism spectrum disorders: evidence of publication bias.

Authors:  Melisa Carrasco; Fred R Volkmar; Michael H Bloch
Journal:  Pediatrics       Date:  2012-04-23       Impact factor: 7.124

2.  Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.

Authors:  Denis G Sukhodolsky; Lawrence Scahill; Kenneth D Gadow; L Eugene Arnold; Michael G Aman; Christopher J McDougle; James T McCracken; Elaine Tierney; Susan Williams White; Luc Lecavalier; Benedetto Vitiello
Journal:  J Abnorm Child Psychol       Date:  2007-08-03

3.  Computational modeling of interventions for developmental disorders.

Authors:  Michael S C Thomas; Anna Fedor; Rachael Davis; Juan Yang; Hala Alireza; Tony Charman; Jackie Masterson; Wendy Best
Journal:  Psychol Rev       Date:  2019-06-06       Impact factor: 8.934

4.  Treatment of Autism Spectrum Disorder in Children and Adolescents.

Authors:  Melissa DeFilippis; Karen Dineen Wagner
Journal:  Psychopharmacol Bull       Date:  2016-08-15

Review 5.  Autism spectrum disorders: update of evaluation and treatment.

Authors:  A G Mikhail; B H King
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

6.  Effect of Fluoxetine on Obsessive-Compulsive Behaviors in Children and Adolescents With Autism Spectrum Disorders: A Randomized Clinical Trial.

Authors:  Dinah S Reddihough; Catherine Marraffa; Anissa Mouti; Molly O'Sullivan; Katherine J Lee; Francesca Orsini; Philip Hazell; Joanna Granich; Andrew J O Whitehouse; John Wray; David Dossetor; Paramala Santosh; Natalie Silove; Michael Kohn
Journal:  JAMA       Date:  2019-10-22       Impact factor: 56.272

7.  A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.

Authors:  Tolga Atilla Ceranoglu; Janet Wozniak; Ronna Fried; Maribel Galdo; Barbora Hoskova; Melissa DeLeon Fong; Joseph Biederman; Gagan Joshi
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-11-16       Impact factor: 2.576

8.  Risperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J mice.

Authors:  Dionisio A Amodeo; Joshua H Jones; John A Sweeney; Michael E Ragozzino
Journal:  Autism Res       Date:  2014-06-03       Impact factor: 5.216

Review 9.  Advances in the treatment of fragile X syndrome.

Authors:  Randi J Hagerman; Elizabeth Berry-Kravis; Walter E Kaufmann; Michele Y Ono; Nicole Tartaglia; Ave Lachiewicz; Rebecca Kronk; Carol Delahunty; David Hessl; Jeannie Visootsak; Jonathan Picker; Louise Gane; Michael Tranfaglia
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

Review 10.  Developing drugs for core social and communication impairment in autism.

Authors:  David J Posey; Craig A Erickson; Christopher J McDougle
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2008-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.